Wyeth Rapamune Boxed Warning On Lung Transplants Added To Labeling
Executive Summary
Wyeth has added a boxed warning to Rapamune labeling to reflect an increased incidence of bronchial anastomotic dehiscence in de novo lung transplant patients administered the immunosuppressant
You may also be interested in...
J&J Cypher Stent Approval Includes Rapamune Label Change Monitoring
Post-marketing commitments for Johnson & Johnson/ Cordis' Cypher sirolimus-eluting stent include close monitoring of labeling changes for Wyeth's sirolimus product Rapamune
J&J Cypher Stent Approval Includes Rapamune Label Change Monitoring
Post-marketing commitments for Johnson & Johnson/ Cordis' Cypher sirolimus-eluting stent include close monitoring of labeling changes for Wyeth's sirolimus product Rapamune
Rapamune cyclosporine-sparing regimen approved
New regimen for Wyeth's Rapamune (sirolimus) will allow patients at low to moderate immunologic risk to stop taking cyclosporine two to four months after kidney transplantation and receive higher doses of Rapamune. Clinical research to assess the safety and efficacy of cyclosporine withdrawal in high-risk patients and patients who have been taking a combination of immunosuppressive medications for more than four months is underway, an April 11 1FDA "Talk Paper" states. An FDA advisory committee voted five to four that the Rapamune cyclosporine-sparing data were not sufficient for approval (2"The Pink Sheet" Jan. 28, 2002, p. 11)...